GemVax&KAEL Co.Ltd (KQ:082270) — Stock Price
GemVax&KAEL Co.Ltd (KQ:082270) is currently trading at ₩13030.00 KRW, up 8.86% today. Over the past 52 weeks, shares have ranged between ₩9190.00 and ₩59300.00. This page tracks GemVax&KAEL Co.Ltd's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 082270 market cap overview.
GemVax&KAEL Co.Ltd (082270) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GemVax&KAEL Co.Ltd's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
GemVax&KAEL Co.Ltd Income Statement — Revenue, Profit & Earnings by Year
GemVax&KAEL Co.Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩81.53 Billion | ₩62.69 Billion | ₩72.21 Billion | ₩75.80 Billion | ₩60.37 Billion |
| Cost of Revenue | ₩46.61 Billion | ₩42.98 Billion | ₩46.16 Billion | ₩53.94 Billion | ₩41.49 Billion |
| Gross Profit | ₩34.93 Billion | ₩19.72 Billion | ₩26.05 Billion | ₩21.86 Billion | ₩18.88 Billion |
| Research & Development | ₩14.63 Billion | ₩35.06 Billion | ₩15.67 Billion | ₩11.63 Billion | ₩7.24 Billion |
| SG&A | ₩5.27 Billion | ₩21.45 Billion | ₩16.84 Billion | ₩12.97 Billion | ₩14.00 Billion |
| Total Operating Expenses | ₩77.97 Billion | ₩126.33 Billion | ₩80.08 Billion | ₩79.38 Billion | ₩62.82 Billion |
| Operating Income | ₩3.57 Billion | ₩-38.68 Billion | ₩-13.57 Billion | ₩321.55 Million | ₩-2.48 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | ₩-2.45 Billion |
| Interest Expense | ₩6.65 Billion | ₩3.16 Billion | ₩462.86 Million | ₩445.31 Million | ₩404.96 Million |
| Income Before Tax | ₩-11.43 Billion | ₩-87.80 Billion | ₩-27.35 Billion | ₩-19.60 Billion | ₩12.06 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ₩-11.34 Billion | ₩-87.22 Billion | ₩-27.18 Billion | ₩-19.60 Billion | ₩12.06 Billion |
GemVax&KAEL Co.Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GemVax&KAEL Co.Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩158.87 Billion | ₩150.75 Billion | ₩135.15 Billion | ₩151.14 Billion | ₩172.34 Billion |
| Total Current Assets | ₩42.91 Billion | ₩25.17 Billion | ₩33.73 Billion | ₩60.14 Billion | ₩52.61 Billion |
| Cash & Equivalents | — | ₩2.98 Billion | ₩16.52 Billion | ₩15.80 Billion | ₩18.72 Billion |
| Short-term Investments | ₩5.20 Billion | ₩3.70 Billion | ₩4.18 Billion | ₩23.31 Billion | ₩13.08 Billion |
| Net Receivables | ₩4.76 Billion | ₩8.21 Billion | ₩4.82 Billion | ₩3.84 Billion | ₩6.82 Billion |
| Inventory | ₩8.67 Billion | ₩5.69 Billion | ₩6.78 Billion | ₩10.84 Billion | ₩7.50 Billion |
| Property, Plant & Equipment | — | ₩36.55 Billion | ₩37.50 Billion | ₩32.48 Billion | ₩26.34 Billion |
| Goodwill | ₩0.00 | ₩46.82 Million | ₩1.57 Billion | ₩0.00 | ₩0.00 |
| Total Liabilities | ₩101.65 Billion | ₩121.74 Billion | ₩27.13 Billion | ₩16.79 Billion | ₩18.35 Billion |
| Total Current Liabilities | ₩65.44 Billion | ₩70.27 Billion | ₩25.99 Billion | ₩15.82 Billion | ₩16.14 Billion |
| Long-term Debt | ₩10.00 Billion | ₩22.54 Billion | ₩1.00 Million | ₩0.00 | ₩1.00 Million |
| Net Debt | ₩39.97 Billion | ₩67.05 Billion | — | — | — |
| Total Stockholder Equity | ₩57.23 Billion | ₩29.01 Billion | ₩108.02 Billion | ₩134.35 Billion | ₩153.99 Billion |
| Retained Earnings | ₩-78.42 Billion | ₩-183.42 Billion | ₩-94.08 Billion | ₩-65.85 Billion | ₩-46.65 Billion |
GemVax&KAEL Co.Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GemVax&KAEL Co.Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩1.11 Billion | ₩-28.37 Billion | ₩3.57 Billion | ₩-2.96 Billion | ₩-3.47 Billion |
| Capital Expenditures | ₩2.11 Billion | ₩3.49 Billion | ₩8.46 Billion | ₩9.09 Billion | ₩6.87 Billion |
| Free Cash Flow | ₩-1.01 Billion | ₩-32.06 Billion | ₩-5.55 Billion | ₩-13.79 Billion | ₩-12.98 Billion |
| Investing Cash Flow | — | ₩-50.04 Billion | ₩-10.51 Billion | ₩6.49 Billion | ₩-28.07 Billion |
| Financing Cash Flow | — | ₩65.41 Billion | ₩7.74 Billion | ₩-5.98 Billion | ₩-661.11 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩4.31 Billion | ₩4.01 Billion | ₩3.69 Billion | ₩2.86 Billion | ₩2.31 Billion |
| Change in Cash | ₩14.00 Billion | ₩-12.94 Billion | ₩720.02 Million | ₩-2.92 Billion | ₩-32.05 Billion |
GemVax&KAEL Co.Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track GemVax&KAEL Co.Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | 38.93 | — | — |
| Sep 30, 2025 | -60.22 | — | — |
| Jun 30, 2025 | -38.52 | — | — |
| May 14, 2025 | -223.35 | — | — |
| Mar 19, 2025 | -1177.66 | — | — |
| Nov 12, 2024 | -206.30 | — | — |
| Aug 14, 2024 | 55.68 | — | — |
| May 16, 2024 | -875.51 | — | — |